Demand
← Отчётные звонки
01
02
03
04 05 06
Тон
AI
Капзатраты
A1 A2
TMO
FY2026 Q2
Повышен
Отчётный звонок Thermo Fisher Scientific Inc
Вывод Buzzberg
Revenue grew 10% to $11.99 billion
Thermo Fisher reported a strong Q2 with 5% organic growth and 13% EPS growth, beating expectations. Management raised full-year guidance, citing improving customer activity across end markets, especially pharma/biotech. Acquisitions (Clario, filtration/separation) are performing well, and the company continues to invest in innovation and share gains. Q2 revenue $11.99B (+10% reported, +5% organic); adj EPS $6.03 (+13%) – above prior guidance.
Вывод Buzzberg Revenue grew 10% to $11.99 billion Thermo Fisher reported a strong Q2 with 5% organic growth and 13% EPS growth, beating expectations. Management raised full-year guidance, citing improving customer activity across end markets, especially pharma/biotech. Acquisitions (Clario, filtration/separation) are performing well, and the company continues to invest in innovation and share gains. Q2 revenue $11.99B (+10% reported, +5% organic); adj EPS $6.03 (+13%) – above prior guidance. Читать полный анализСвернуть анализ
Thermo Fisher reported a strong Q2 with 5% organic growth and 13% EPS growth, beating expectations. Management raised full-year guidance, citing improving customer activity across end markets, especially pharma/biotech. Acquisitions (Clario, filtration/separation) are performing well, and the company continues to invest in innovation and share gains. Q2 revenue $11.99B (+10% reported, +5% organic); adj EPS $6.03 (+13%) – above prior guidance.
- Full-year revenue guidance raised to $47.4-48.1B; EPS raised to $24.93-25.33.
- Pharma/biotech end market grew mid-single digits with strong bioproduction and clinical research.
- Academic/government grew low single digits, returning to growth; US positive.
Выручка$11.994B+9% к/к
EPS$6.03+11% к/к
Валовая маржа41.21%Факт
Операционная маржа17.4%Факт
6 подтверждённых тезисов
Что важно сейчас
Самые значимые изменения по итогам звонка.
Margins
Adjusted operating margin expanded 90 bps to 22.8%
Guidance
Raised full-year revenue guidance to $47.4-$48.1B
Показать ещё 3 тезиса
Capital return
Deployed $1.2B to shareholders via buybacks and dividends
Demand
Bioproduction had another quarter of excellent growth
Other
Actively deploying AI across the company
Отчётный период
Фактические результаты
| Показатель | Факт | Изменение |
|---|---|---|
| Выручка | $11.994B | +9% к/к |
| EPS | $6.03 | +11% к/к |
| Валовая маржа | 41.21% | Факт |
| Операционная маржа | 17.4% | Факт |
| Свободный денежный поток | $1.675B | Факт |
| Капзатраты | $0.45B | Факт |
Прогнозные данные
Прогноз компании
| Показатель | Период | Диапазон | Середина | Статус |
|---|---|---|---|---|
| EPS | FY2026 | $24.93–$25.33 | $25.13 | Повышен |
| Выручка | FY2026 | $47.4B–$48.1B | $47.75B | Повышен |
AI, капзатраты и спрос
Оценка менеджмента
confident
Management struck a confident tone, citing an outstanding quarter, a clean top and bottom line beat, and raising full-year guidance. The tone was driven by strong customer activity across end markets and excellent operational execution.
Оценка AI от менеджмента
Management discussed launching next-generation Orbitrap platforms and AI-driven capabilities at the ASMS conference, and stated they are actively deploying AI across the company to further accelerate PPI's impact.
Инвестиции и мощности
Net capital expenditures for 2026 are expected to be between $1.9 and $2.1 billion; $800 million was spent in the first half. Management also noted they are increasing capacity for the filtration and separation business.
все упомянутые компании ниже: 2
Компаниис момента звонка
Цепочка поставок
Цепочка поставок
Marc Casper
Electron microscopy strength partly attributed to semiconductor enabling role, with strong bookings growth. — Suggests ongoing capital equipment demand in semiconductor manufacturing, benefiting tool suppliers and potentially reinforcing capex cycle narratives.
Доказательства
“Within electron microscopy, another really good quarter, semiconductor, we play a key enabling role there”
Внешние сигналы
Альфа цепочки поставок · 2с момента звонка
Chemical analysis business growth was driven by higher commodity prices and increased demand for safety/security applications (radiation and explosives detection) due to global conflict.
Доказательства
“We also saw an increase in demand for safety and security applications as well, given the amount of conflict going on in the world.”
Electron microscopy strength partly attributed to semiconductor enabling role, with strong bookings growth.
Методология и полнота
Анализ основан только на заявлениях менеджмента. Показаны все подтверждённые упоминания компаний: 2. Фактические результаты и прогнозы разделены. Публичные доказательства ограничены восемью короткими атрибутированными цитатами. AI-анализ может быть неполным или ошибочным — проверяйте важные утверждения по первоисточнику.